Additional Valerian Safety Data Needed To Gain OTC Status, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Additional data on valerian's safety must be provided to FDA before the agency can consider including the botanical in the final monograph for OTC nighttime sleep aid drugs, FDA states in an April 7 letter to European-American Phytomedicines Coalition (EAPC) counsel Robert Pinco